Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 4, 2024

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 28, 2024

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 27, 2024

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

GlobeNewswire February 21, 2024

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

GlobeNewswire February 1, 2024

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2024

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2023

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

GlobeNewswire October 31, 2023

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

GlobeNewswire October 31, 2023

Mersana Therapeutics Announces Changes in Leadership

GlobeNewswire September 6, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

Newsfile August 22, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

PR Newswire August 18, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

Newsfile August 14, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

PR Newswire August 10, 2023

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

GlobeNewswire August 8, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

PR Newswire August 4, 2023

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 4, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

Newsfile July 31, 2023

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

GlobeNewswire July 27, 2023